Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine: Interim results of a double-blind, randomised controlled phase 1 and 2 trial

Summary: Background: Nanocovax is a recombinant severe acute respiratory syndrome coronavirus 2 subunit vaccine composed of full-length prefusion stabilized recombinant SARS-CoV-2 spike glycoproteins (S-2P) and aluminium hydroxide adjuvant. Methods: We conducted a dose-escalation, open label trial...

Full description

Saved in:
Bibliographic Details
Main Authors: Thuy P. Nguyen, Quyet Do, Lan T. Phan, Duc V. Dinh, Hiep Khong, Luong V. Hoang, Thuong V. Nguyen, Hung N. Pham, Men V. Chu, Toan T. Nguyen, Quang D. Pham, Tri M. Le, Tuyen N.T. Trang, Thanh T. Dinh, Thuong V. Vo, Thao T. Vu, Quynh B.P. Nguyen, Vuong T. Phan, Luong V. Nguyen, Giang T. Nguyen, Phong M. Tran, Thuan D. Nghiem, Tien V. Tran, Tien G. Nguyen, Tuynh Q. Tran, Linh T. Nguyen, Anh T. Do, Dung D. Nguyen, Son A. Ho, Viet T. Nguyen, Dung T. Pham, Hieu B. Tran, Son T. Vu, Su X. Hoang, Trung M. Do, Xuan T. Nguyen, Giang Q. Le, Ton Tran, Thang M. Cao, Huy M. Dao, Thao T.T. Nguyen, Uyen Y Doan, Vy T.T. Le, Linh P. Tran, Ngoc M. Nguyen, Ngoc T. Nguyen, Hang T.T. Pham, Quan H. Nguyen, Hieu T. Nguyen, Hang L.K. Nguyen, Vinh T. Tran, Mai T.N. Tran, Truc T.T. Nguyen, Phat T. Ha, Hieu T. Huynh, Khanh D. Nguyen, Ung T. Thuan, Chung C. Doan, Si M. Do
Format: Artigo
Language:Inglês
Published: Elsevier 2022-07-01
Series:The Lancet Regional Health. Western Pacific
Subjects:
SARS-CoV-2
Spike protein
Protein sub-unit vaccine
Immunogenicity
Phase 1 and 2 clinical trial
Online Access:http://www.sciencedirect.com/science/article/pii/S266660652200089X
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items